Results 41 to 50 of about 21,749 (235)

Tetranectin as a potential biomarker in heart failure with ejection fraction >45%: A prospective cohort study

Romanian Journal of Internal Medicine
Heart failure (HF) with left ventricle ejection fraction (LVEF) >45% lacks reliable biomarkers for risk stratification complicating its management, as it encompasses both heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%) and mildly ...
Vulciu Paula Alexandra, Pilat Luminita, Varga Norberth-Istvan, Dascau Voicu, Popa Calin, Mot Maria-Daniela, Barata Paula Irina, Donath Miklos Imola, Puschita Maria   +8 more
doaj   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future

Reviews in Cardiovascular Medicine
This review aims to summarize the status and future directions of pediatric heart failure (HF) pharmacotherapy. Notably, managing HF in children presents unique challenges due to heterogeneous etiologies and a longstanding paucity of pediatric-specific ...
Bibhuti B Das
doaj   +1 more source

Do we need a definition of acute heart failure with preserved ejection fraction?

Annals of Medicine, 2021
Heart failure with preserved ejection fraction (HFpEF) might soon become the most prevalent type of acute heart failure. Still, despite more than 30 years of research on HFpEF, not only do we lack specific treatment, but also a generally accepted ...
Agnieszka Kapłon-Cieślicka, Lars H. Lund   +1 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Impact of severe secondary tricuspid regurgitation on rest and exercise hemodynamics of patients with heart failure and a preserved left ventricular ejection fraction

Frontiers in Cardiovascular Medicine, 2023
BackgroundBoth secondary tricuspid regurgitation (STR) and heart failure with preserved ejection fraction (HFpEF) are relevant public health problems in the elderly population, presenting with potential overlaps and sharing similar risk factors. However,
Claudia Baratto, Sergio Caravita, Sergio Caravita, Giorgia Corbetta, Giorgia Corbetta, Davide Soranna, Antonella Zambon, Antonella Zambon, Céline Dewachter, Mara Gavazzoni, Francesca Heilbron, Michele Tomaselli, Noela Radu, Francesco Paolo Perelli, Francesco Paolo Perelli, Giovanni Battista Perego, Jean-Luc Vachiéry, Gianfranco Parati, Gianfranco Parati, Luigi P. Badano, Luigi P. Badano, Denisa Muraru, Denisa Muraru   +22 more
doaj   +1 more source

Smartphone, Mom, and HFpEF

JACC: Heart Failure, 2018
![Figure][1] I had the wonderful opportunity to spend time with my mom over the holidays. For her 88th birthday 6 months ago, we presented her with a smartphone, a new challenging technology that she was reluctant to adopt given that she had a flip phone for over a decade.
openaire   +2 more sources

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?

Sakarya Tıp Dergisi
Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened.
Dilan Damla Ozturk, Fatih Necip Arıcı, Cigdem Erhan, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, Ugur Can Izlimek, Cahit Dincer, Ahmet Gazi Mustan, Çisem Yılmaz, Tayyibe Saler, Hilmi Erdem Sümbül, Erdinc Gulumsek, Hüseyin Ali Öztürk   +13 more
doaj   +1 more source

Heart failure with preserved ejection fraction: A short review of diagnosis and management [PDF]

КардиоСоматика
Around 64 million persons in the world have heart failure (HF). HF patients with left ventricle ejection fraction (LVEF) of ≥50% are classified as having HF with preserved ejection fraction (HFpEF).
Sidhi Laksono, Prita Saskya Prameswari
doaj   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source